Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and ...

Jaime Almandoz, MD, MBA, of UT Southwestern Medical Center, speaks on results of a study that investigated tirzepatide uptake ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.

A large population-based study found that GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors (SGLT2is), two classes of ...

Medicaid plans often put up barriers around newer classes of diabetes medications that offer cardioprotection, according to a ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, are expected to have driven the company's top line.

Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary ...

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step closer to hitting the ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.